Acute dopamine D1 and D2 receptor stimulation does not modulate mismatch negativity (MMN) in healthy human subjects

Psychopharmacology

Volumn 194, Issue 4, 2007, Pages 443-451

  Leung, Sumie ^a   Croft, Rodney J ^a,b   Baldeweg, Torsten ^c,d   Nathan, Pradeep J ^a,b  

^a SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

D1 receptors; D2 receptors; Dopamine (DA); Glutamate; Mismatch negativity (MMN); NMDA receptors; Schizophrenia

Indexed keywords

BROMOCRIPTINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; PERGOLIDE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EVOKED AUDITORY RESPONSE; HUMAN; LATENT PERIOD; MALE; MISMATCH NEGATIVITY; NEUROMODULATION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR UPREGULATION;

ACOUSTIC STIMULATION; ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; BROMOCRIPTINE; CONTINGENT NEGATIVE VARIATION; CROSS-OVER STUDIES; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; EVOKED POTENTIALS, AUDITORY; HUMANS; MALE; PERGOLIDE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 34848814454     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0865-1     Document Type: Article

References (63)

1. Ahveninen J, Kahkonen S, Pennanen S, Liesivuori J, Ilmoniemi RJ, Jaaskelainen IP (2002) Tryptophan depletion effects on EEG and MEG responses suggest serotonergic modulation of auditory involuntary attention in humans. Neuroimage 16:1052-1061
2. Baker K, Baldeweg T, Sivagnanasundaram S, Scambler P, Skuse D (2005) COMT Val108/158 Met modifies mismatch negativity and cognitive function in 22q11 deletion syndrome. Biol Psychiatry 58:23-31
3. Baldeweg T, Klugman A, Gruzelier JH, Hirsch SR (2002) Impairment in frontal but not temporal components of mismatch negativity in schizophrenia. Int J Psychophysiol 43:111-122
4. Baldeweg T, Klugman A, Gruzelier J, Hirsch SR (2004) Mismatch negativity potentials and cognitive impairment in schizophrenia. Schizophr Res 69:203-217
5. Baldeweg T, Wong D, Stephan KE (2006) Nicotinic modulation of human auditory sensory memory: Evidence from mismatch negativity potentials. Int J Psychophysiol 59:49-58
6. Bartholomeusz CF, Box G, Van Rooy C, Nathan PJ (2003) The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans. J Psychopharmacol 17:9-15
7. Bramon E, Croft RJ, McDonald C, Virdi GK, Gruzelier JG, Baldeweg T, Sham PC, Frangou S, Murray RM (2004) Mismatch negativity in schizophrenia: a family study. Schizophr Res 67:1-10
8. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D (1998) Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29:142-147
9. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
10. Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci 13:272-276
11. Checkley SA (1980) Neuroendocrine tests of monoamine function in man: a review of basic theory and its application to the study of depressive illness. Psychol Med 10:35-53
12. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatryyiatr 148:1474-1486
13. Drago F, Scapagnini U (1986) Hormonal modulation of central dopaminergic transmission. J Neural Transm, Suppl 22:47-54
14. Ellis KA, Nathan PJ (2001) The pharmacology of human working memory. Int J Neuropsychopharmacol 4:299-313
15. Frodl-Bauch T, Kathmann N, Möller H-J, Hegerl U (1997) Dipole localization and test-restest reliability of frequency and duration mismatch negativity generator processes. Brain Topogr 10:3-8
16. Giard M-H, Lavikainen J, Reinikainen K, Perrin F, Bertrand O, Pernier J, Näätänen R (1995) Separate representation of stimulus frequency, intensity and duration in auditory sensory memory: an event-related potential and dipole-model analysis. J Cogn Neurosci 7:133-143
17. Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr Bull 26:119-136
18. Inami R, Kirino E, Inoue R, Arai H (2005) Transdermal nicotine administration enhances automatic auditory processing reflected by mismatch negativity. Pharmacol Biochem Behav 80:453-461
19. Iversen SD, Iversen LL (2007) Dopamine: 50 years in perspective. Trends Neurosci 30:188-193
20. Javitt DC (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9:984-997, 979
21. Javitt DC, Doneshka P, Zylberman I, Ritter W, Vaughan HG Jr (1993) Impairment of early cortical processing in schizophrenia: an event-related potential confirmation study. Biol Psychiatry 33:513-519
22. Javitt DC, Steinschneider M, Schroeder CE, Arezzo JC (1996) Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci USA 93:11962-11967
23. Kähkönen S, Ahveninen J, Jaaskelainen IP, Kaakkola S, Naatanen R, Huttunen J, Pekkonen E (2001) Effects of haloperidol on selective attention: a combined whole-head MEG and high-resolution EEG study. Neuropsychopharmacology 25:498-504
24. Kähkönen S, Ahveninen J, Pekkonen E, Kaakkola S, Huttunen J, Ilmoniemi RJ, Jääskeläinen IP (2002) Dopamine modulates involuntary attention shifting and reorienting: an electromagnetic study. Clin Neurophysiol 113:1894-1902
25. Kähkönen S, Makinen V, Jaaskelainen IP, Pennanen S, Liesivuori J, Ahveninen J (2005) Serotonergic modulation of mismatch negativity. Psychiatry Res 138:61-74
26. Kapur S, Seeman P (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 7:837-844
27. Kathmann N, Frodl-Bauch T, Hegerl U (1999) Stability of the mismatch negativity under different stimulus and attention conditions. Clin Neurophysiol 110:317-323
28. Knott V, Blais C, Scherling C, Camarda J, Millar A, Fisher D, McIntosh J (2006a) Neural effects of nicotine during auditory selective attention in smokers: an event-related potential study. Neuropsychobiology 53:115-126
29. Knott VJ, Scherling CS, Blais CM, Camarda J, Fisher DJ, Millar A, McIntosh JF (2006b) Acute nicotine fails to alter event-related potential or behavioral performance indices of auditory distraction in cigarette smokers. Nicotine Tob Res 8:263-273
30. Kujala T, Tervaniemi M, Schroger E (2007) The mismatch negativity in cognitive and clinical neuroscience: Theoretical and methodological considerations. Biol Psychol 74:1-19
31. Laruelle M, Kegeles LS, Abi-Dargham A (2003) Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci 1003:138-158
32. Liddle PF (2000) Cognitive impairment in schizophrenia: its impact on social functioning. Acta Psychiatr Scand, Suppl 400:11-16
33. Light GA, Braff DL (2005) Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry 62:127-136
34. Luciana M, Depue RA, Arbisi P, Leon A (1992) Facilitation of working memory in humans by a D2 dopamine receptor agonist. J Cogn Neurosci 4:58-68
35. Markham A, Benfield P (1997) Pergolide, A review of its pharamacology and therapeutic use in Parkinson's disease. CNS Drugs 7:328-340
36. Mehta MA, Riedel WJ (2006) Dopaminergic enhancement of cognitive function. Curr Pharm Des 12:2487-2500
37. Michie PT, Budd TW, Todd J, Rock D, Wichmann H, Box J, Jablensky AV (2000) Duration and frequency mismatch negativity in schizophrenia. Clin Neurophysiol 111:1054-1065
38. Moore H, West AR, Grace AA (1999) The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. Biol Psychiatry 46:40-55
39. Muller U, von Cramon DY, Pollmann S (1998) D1- versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci 18:2720-2728
40. Näätänen R (1992) Attention and brain function. Erlbaum, Hillsdale, NJ
41. Näätänen R (2000) Mismatch negativity (MMN): perspectives for application. Int J Psychophysiol 37:3-10
42. Näätänen R, Winkler I (1999) The concept of auditory stimulus representation in cognitive neuroscience. Psychol Bull 125:826-859
43. Nakagome K, Ichikawa I, Kanno O, Akaho R, Suzuki M, Takazawa S, Watanabe H, Kazamatsuri H (1998) Overnight effects of triazolam on cognitive function: an event-related potentials study. Neuropsychobiology 38:232-240
44. Pang EW, Fowler B (1999) Dissociation of the mismatch negativity and processing negativity attentional waveforms with nitrous oxide. Psychophysiology 36:552-558
45. Pekkonen E (2000) Mismatch negativity in aging and in Alzheimer's and Parkinson's diseases. Audiol Neuro-Otol 5:216-224
46. Pekkonen E, Hirvonen J, Ahveninen J, Kähkönen S, Kaakkola S, Huttunen J, Jääskeläinen IP (2002) Memory-based comparison process not attenuated by Haloperidol: a combined MEG and EEG study. Neuroreport 13:177-181
47. Rinne T, Alho K, Ilmoniemi RJ, Virtanene J, Näätänen R (2000) Separate time behaviors of the temporal and frontal mismatch negativity sources. Neuroimage 12:14-19
48. Rosburg T, Marinou V, Haueisen J, Smesny S, Sauer H (2004) Effects of lorazepam on the neuromagnetic mismatch negativity (MMNm) and auditory evoked field component N100m. Neuropsychopharmacology 29:1723-1733
49. Sato Y, Yabe H, Todd J, Michie P, Shinozaki N, Sutoh T, Hiruma T, Nashida T, Matsuoka T, Kaneko S (2003) Impairment in activation of a frontal attention-switch mechanism in schizophrenic patients. Biol Psychol 62:49-63
50. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73
51. Serra JM, Escera C, Sanchez-Turet M, Sanchez-Sastre J, Grau C (1996) The H1-receptor antagonist chlorpheniramine decreases the ending phase of the mismatch negativity of the human auditory event-related potentials. Neurosci Lett 203:77-80
52. Shelley AM, Ward PB, Catts SV, Michie PT, Andrews S, McConaghy N (1991) Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biol Psychiatry 30:1059-1062
53. Sinkkonen J, Tervaniemi M (2000) Towards optimal recording and analysis of the mismatch negativity. Audiol Neuro-Otol 5:235-246
54. Smolnik R, Pietrowsky R, Fehm HL, Born J (1998) Enhanced selective attention after low-dose administration of the benzodiazepine antagonist flumazenil. J Clin Psychopharmacol 18:241-247
55. Todd J, Michie PT, Jablensky AV (2003) Association between reduced duration mismatch negativity (MMN) and raised temporal discrimination thresholds in schizophrenia. Clin Neurophysiol 114:2061-2070
56. Trantham-Davidson H, Neely LC, Lavin A, Seamans JK (2004) Mechanisms underlying differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal cortex. J Neurosci 24:10652-10659
57. Tseng KY, O'Donnell P (2004) Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J Neurosci 24:5131-5139
58. Tzschentke TM (2001) Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 63:241-320
59. Umbricht D, Krljes S (2005) Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 76:1-23
60. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC (2000) Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57:1139-1147
61. Umbricht D, Koller R, Vollenweider FX, Schmid L (2002) Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry 51:400-406
62. Umbricht D, Vollenweider FX, Schmid L, Grübel C, Skrabo A, Huber T, Koller R (2003) Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology 28:170-181
63. Wu Y, Pearl SM, Zigmond MJ, Michael AC (2000) Inhibitory glutamatergic regulation of evoked dopamine release in striatum. Neuroscience 96:65-72